Quantum BioPharma (NASDAQ: QNTM) signs deal with Thermo Fisher to launch Phase 2 trial of Lucid-MS, a first-in-class neuroprotective therapy targeting progressive multiple sclerosis. FDA cleared the IND just two months ago. #MultipleSclerosis #Biopharma

Quantum BioPharma (QNTM) signs a Study Start-Up Agreement with Thermo Fisher Scientific to launch a Phase 2 trial of Lucid-MS, a novel neuroprotective MS therapy targeting demyelination rather than immune suppression. #MultipleSclerosis #Biopharma

Silo Pharma (NASDAQ: SILO) receives U.S. Patent Notice of Allowance for SPC-15, its intranasal PTSD therapeutic. A matching patent was already granted in Japan, strengthening Silo's global IP strategy as it advances development of this promising treatment. #PTSD #Biopharma

Quantum BioPharma (NASDAQ: QNTM) is developing Lucid-MS, targeting the enzyme behind myelin destruction in MS patients. With ~3 million people affected globally and no approved therapy reversing neurodegeneration, this candidate could fill a critical gap. #MultipleSclerosis #Biopharma

Quantum BioPharma (NASDAQ: QNTM) is developing Lucid-MS, targeting the enzyme behind myelin destruction in MS patients. With ~3 million people affected globally and no approved therapy reversing neurodegeneration, this candidate could fill a critical gap. #MultipleSclerosis #Biopharma

Quantum BioPharma (NASDAQ: QNTM) has received FDA approval to advance Lucid-MS into phase 2 clinical trials for multiple sclerosis. The drug showed a strong safety profile in phase 1 and uses a distinct mechanism from existing MS therapies. #Biopharma #MultipleSclerosis

Quantum BioPharma (NASDAQ: QNTM) receives FDA approval to advance Lucid-MS into Phase 2 clinical trials for multiple sclerosis. The drug showed a strong safety profile in Phase 1 and features a proprietary mechanism that sets it apart from existing therapies. #Biopharma #MultipleSclerosis

Quantum BioPharma (NASDAQ: QNTM) signs Study Start-Up Agreement with Thermo Fisher Scientific to advance its Phase 2 trial of Lucid-MS, a first-in-class neuroprotective treatment for progressive multiple sclerosis. #MultipleSclerosis #Biopharma

Lantern Pharma (NASDAQ: LTRN) closes a $4M registered direct offering at $1.09/share, with warrants that could yield an additional $4M. Proceeds fuel its AI-driven precision oncology pipeline. #Biopharma #Oncology